Design, Synthesis, Molecular Docking, Dynamics Simulation, and Biological Evaluation of Novel Thiazolidinedione Derivatives Against Breast Cancer with Apoptosis-Inducing Activity

Breast cancer remains one of the leading causes of cancer-related deaths among women worldwide. The chemotherapeutic drugs used in treatment often have serious side effects. In light of their anticancer potential, thiazolidinedione (TZD) derivatives are considered to be promising candidates for the development of novel antitumor agents. The objective of this study is to synthesize and produce two sets of TZD derivatives by combining the structural features of microtubule-targeting drugs used in breast cancer treatment, and to determine their molecular docking, molecular dynamics simulations, ADMET profile, antiproliferative, and apoptotic effect potential. In the present study, PZ-11 was determined by xCELLigence analysis to have the highest antiproliferative potential among all compounds tested on MCF-7 breast cancer cells. The cytotoxic activity of the synthesized compounds was evaluated against MCF-7 breast cancer cells, revealing IC<sub>50</sub> values of 29.44 μM for PZ-9 and 17.35 μM for PZ-11, compared to 6.45 μM for the reference drug vincristine. Analysis of the gene expression of the PZ-11 compound, which has a stronger cytotoxic effect potential, showed that PZ-11 significantly downregulates <i>AIFM1, BAG3</i>, and <i>BIRC3</i>, while upregulating pro-apoptotic genes such as <i>BAD, HRK, CASP10</i>, and <i>CASP14</i>. PZ-11's binding affinities were screened using a molecular docking workflow via KNIME. The robust and persistent interactions between PZ-11 and AIF were substantiated by molecular dynamics simulation. It is demonstrated by ADMET predictions that PZ compounds possess suitable pharmacokinetic properties. PZ-11 is a promising TZD-based anticancer drug candidate against breast cancer cells, as determined by computational and experimental analysis. However, further validation is required through <i>in vivo</i> analysis to support these findings.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2025-12-23
DOI
https://doi.org/10.1021/acsomega.5c07713
Primary Topic
Synthesis and biological activity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Design, Synthesis, Molecular Docking, Dynamics Simulation, and Biological Evaluation of Novel Thiazolidinedione Derivatives Against Breast Cancer with Apoptosis-Inducing Activity

Ates‐Alagoz Zeynep, Sarah Gado, Pelin Mutlu, Ali Farhang Boroujeni et al.
ACS Omega
Synthesis and biological activity
article

Design, Synthesis, Molecular Docking, Dynamics Simulation, and Biological Evaluation of Novel Thiazolidinedione Derivatives Against Breast Cancer with Apoptosis-Inducing Activity

Ates‐Alagoz Zeynep, Sarah Gado, Pelin Mutlu, Ali Farhang Boroujeni, Pouria Zarrin, Demet Cansaran-Duman, Fatma Zeynep Bozkurt, Ibrahim Gadaşlı
article en

Abstract

Breast cancer remains one of the leading causes of cancer-related deaths among women worldwide. The chemotherapeutic drugs used in treatment often have serious side effects. In light of their anticancer potential, thiazolidinedione (TZD) derivatives are considered to be promising candidates for the development of novel antitumor agents. The objective of this study is to synthesize and produce two sets of TZD derivatives by combining the structural features of microtubule-targeting drugs used in breast cancer treatment, and to determine their molecular docking, molecular dynamics simulations, ADMET profile, antiproliferative, and apoptotic effect potential. In the present study, PZ-11 was determined by xCELLigence analysis to have the highest antiproliferative potential among all compounds tested on MCF-7 breast cancer cells. The cytotoxic activity of the synthesized compounds was evaluated against MCF-7 breast cancer cells, revealing IC<sub>50</sub> values of 29.44 μM for PZ-9 and 17.35 μM for PZ-11, compared to 6.45 μM for the reference drug vincristine. Analysis of the gene expression of the PZ-11 compound, which has a stronger cytotoxic effect potential, showed that PZ-11 significantly downregulates <i>AIFM1, BAG3</i>, and <i>BIRC3</i>, while upregulating pro-apoptotic genes such as <i>BAD, HRK, CASP10</i>, and <i>CASP14</i>. PZ-11's binding affinities were screened using a molecular docking workflow via KNIME. The robust and persistent interactions between PZ-11 and AIF were substantiated by molecular dynamics simulation. It is demonstrated by ADMET predictions that PZ compounds possess suitable pharmacokinetic properties. PZ-11 is a promising TZD-based anticancer drug candidate against breast cancer cells, as determined by computational and experimental analysis. However, further validation is required through <i>in vivo</i> analysis to support these findings.

ACS OmegaVol. 11(1)
Ankara University (TR), Czech Academy of Sciences, Institute of Biotechnology (CZ), Graduate School USA (US)
Good health and well-being
Openalex Percentile: Top 33%
Synthesis and biological activity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.